The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center. It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.
This is a retrospective, observational, data analysis of approximately 800 patients who underwent primary Percutaneous Coronary Intervention at our institution since September 2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to Percutaneous Coronary Intervention will be excluded. This analysis is estimated to take 1-2 months.
Study Type
OBSERVATIONAL
Washington Hospital Center
Washington D.C., District of Columbia, United States
All-cause mortality and composite or Q-wave myocardial infarction
6-month rates of all-cause mortality and the composite of all-cause mortality or Q-wave myocardial infarction.
Time frame: Chart review 6 months after PCI
TIMI major bleeding
Thrombolysis In Myocardial Infarction (TIMI) major bleeding during hospital stay.
Time frame: During hospital stay; average stay is less than 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.